UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042414
Receipt number R000048390
Scientific Title Study on the effect of food ingredients on the memory of healthy middle-aged and elderly
Date of disclosure of the study information 2021/04/23
Last modified on 2023/10/11 09:13:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on the effect of food ingredients on the memory of healthy middle-aged and elderly

Acronym

Study on the effect of food ingredients on the memory of healthy middle-aged and elderly

Scientific Title

Study on the effect of food ingredients on the memory of healthy middle-aged and elderly

Scientific Title:Acronym

Study on the effect of food ingredients on the memory of healthy middle-aged and elderly

Region

Japan


Condition

Condition

Healthy subjects

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to examine the effect on memory by continuously ingesting the test food for 12 weeks in healthy Japanese men and women aged 50 to 69 years.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

MCI screen (short-term memory, long-term memory)

Key secondary outcomes

(Secondary outcomes)
Pittsburgh Sleep Quality Index,SF-36v2 Japanese version,PHQ-9 Japanese version
(Safety evaluation)
Vital signs, body measurement(weight,BMI),biochemical tests, hematological tests, adverse events
(Exploratory outcomes)
Satisfaction With Life Scale Japanese version(SWLS;screening only),Participant Background Questionnaire(screening only)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

12-weeks intake of the test food

Interventions/Control_2

12-weeks intake of the placebo food

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit

69 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Japanese men and women whose age at the time of obtaining consent is aged older 50 to 69 years old.
2) Subject who is aware of in cognitive function (memory) decline.
3) Subject who has a MMSE-J score of 24 points or more.
4) PHQ-9 Japanese version with a score of 9 points or less.
5) Subject with an MPI score of 50.20 or higher for their MCI screen.
6) Immediate playback of MCI screen delayed playback less than the number of correct answers for the third time.
7) Non-smoker.
8) Subject who has received sufficient explanation of the purpose and content of the research, have the ability to consent, voluntarily volunteered to participate in the study after understanding it well, and agreed to participate in the study in writing.

Key exclusion criteria

1.Subject who is taking medication or under medical treatment.
2.Subject who is under exercise therapy or dietetic therapy.
3.Subject who has an allergy for test food.
4.Subject who has or had a history of either medicine or alcohol dependence syndrome.
5.Subject who has or had a history of mental illness (depression) or sleep disturbance.
6.Subject who has irregular work rhythms such as working at night and shift work.
7.Subject who has extremely irregular lifestyle such as eating and sleeping.
8.Subject who has an unbalanced diet.
9.Subject who has or had a history of severe diseases such as brain disease, malignant tumor, immune disease, diabetes, liver disease (hepatitis), kidney disease, heart disease, thyroid disease, adrenal disease, other metabolic diseases.
10.Subject who uses health foods, supplements, and pharmaceuticals that affect cognitive function.
11.Subject who has participated in other clinical studies within the past 3 months from the day of the consent acquisition or who is planning to participate in other clinical studies during the current study.
12.Subject who has blood drawn or blood component more than 200mL within the past 1 month or more than 400mL within the past 3 months from the day of the consent acquisition.
13.Subject who is planning to get pregnant after the day of informed consent or is currently pregnant and lactating.
14.Subject who can't keep the daily records.
15.Subject who is judged as an inappropriate candidate according to the screening data.
16.Subject who is considered as an inappropriate candidate by the doctor in charge.

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Daisuke
Middle name
Last name Ochitani

Organization

HUMA R&D CORP

Division name

Clinical Development Division

Zip code

108-0014

Address

Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan

TEL

03-3431-1260

Email

ochitani@huma-rd.co.jp


Public contact

Name of contact person

1st name Daisuke
Middle name
Last name Ochitani

Organization

HUMA R&D CORP

Division name

Clinical Development Division

Zip code

108-0014

Address

Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan

TEL

03-3431-1260

Homepage URL


Email

ochitani@huma-rd.co.jp


Sponsor or person

Institute

HUMA R&D CORP

Institute

Department

Personal name



Funding Source

Organization

ITO EN, Ltd

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

AMC Nishi-Umeda Clinic Clinical Research Institutional Review Board

Address

West Umeda Building 3F 3-3-45 Umeda Kita-ku Osaka Japan,530-0001

Tel

06-4797-5660

Email

jimukyoku@amc-clinc.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 04 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

80

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2020 Year 10 Month 20 Day

Date of IRB

2020 Year 10 Month 22 Day

Anticipated trial start date

2020 Year 11 Month 16 Day

Last follow-up date

2021 Year 04 Month 22 Day

Date of closure to data entry

2021 Year 05 Month 10 Day

Date trial data considered complete

2021 Year 05 Month 26 Day

Date analysis concluded

2024 Year 04 Month 30 Day


Other

Other related information



Management information

Registered date

2020 Year 11 Month 11 Day

Last modified on

2023 Year 10 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048390


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name